About 700 reports

  • 8.6 EDUCATION AND TREATMENT OF PSYCHOLOGICAL FACTORS ACCOMPANYING PLAQUE
  • OUTLINES THE RISK FACTORS AND COMORBIDITIES FOR PLAQUE PSORIASIS.

AND GOODERHAM, M. (2017) ' PSORIASIS, DEPRESSION, AND SUICIDALITY. ', SKIN THERAPY LETTER, ##(##), PP. ##-##.

  • Dermatological Condition
  • Drug Development
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Comorbidities

HEALTH SURV ENGL 2012, ##:##-##.

  • Dermatological Condition
  • Drug Development
  • United States
  • Forecast
  • Pfizer Inc.

The drug claimed blockbuster status just one year after its launch.

  • Drug Development
  • Pharmaceutical
  • Therapy
  • Company
  • Market Size
  • Comorbidities

Figure ## and Figure ## present the one-year total and one-year diagnosed prevalent cases of AD, respectively.

  • Dermatological Condition
  • Epidemiology
  • Pathology
  • United States
  • Forecast
  • 5.3 GLOBAL AND HISTORICAL TRENDS
  • SYMPTOMATIC REPRESENTATIONS OF ACNE

" People with a history of depression, you wouldn' t give Isotretinoin to them, unless you had to, because Isotretinoin can also cause severe depression. "

  • Dermatological Condition
  • Drug Development
  • Foamix Ltd.
  • Galderma S.A.
  • Novan, Inc.
  • 3.2 Global Acne Treatment Market Analysis

This further leads to depression and also development of suicidal tendencies in them.

  • Dermatological Condition
  • Drug Development
  • World
  • Market Size
  • Actavis plc
  • Top Indications for CNS
  • MS Trials as a Percent of CNS Trials

PIPELINE PRODUCTS - REGIONAL BREAKDOWN - - - - - - - - - - - - - - - - - - - - - - - - - Stage US Europe Japan Canada Global Pre-Registration ## ## Filing Rejected/ Withdrawn ## ## Phase III ## ## ## ## Phase II ## ## ## Phase I ## ## ## ## Phase ## IND/ CTA Filed Precl

  • Drug Development
  • United States
  • Biogen Idec Inc.
  • Novartis AG
  • Sanofi S.A.
  • COMORBIDITIES ASSOCIATED WITH ACNE
  • ACNE

Further, it may increase the chance of tension, depression, and suicidal ideation.

  • Dermatological Condition
  • Drug Development
  • Allergan plc
  • Foamix Ltd.
  • Novartis AG
  • ORPHAN AND RARE DERMATOLOGY DRUGS MARKET, GLOBAL, PROGNOSIS FOR
  • 2.1 Therapy Area Overview

This can lead to negative selfimage and mental health disorders such as anxiety and depression.

  • Dermatological Condition
  • Drug Development
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • COMORBIDITIES ASSOCIATED WITH ACNE
  • ACNE

Further, it may increase the chance of tension, depression, and suicidal ideation.

  • Dermatological Condition
  • Drug Development
  • Allergan plc
  • Foamix Ltd.
  • Novartis AG
  • 7.6.3 SAFETY
  • FREQUENTLY REPORTED AES DURING A PHASE III CLINICAL TRIAL COMPARING AZOPT, TRUSOPT, AND

HIGH PREVALENCE OF ANXIETY AND DEPRESSION IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA.

  • Dermatological Condition
  • Drug Development
  • Aerie Pharmaceuticals, Inc.
  • Allergan plc
  • Santen Pharmaceutical Co., Ltd.

India ##.

  • Dermatological Condition
  • Drug Development
  • World
  • Biogen Idec Inc.
  • Eisai Co., Ltd.
  • Race
  • 3.1 DISEASE BACKGROUND

PLAQUE PSORIASIS PATIENTS ARE OFTEN AFFECTED BY DEPRESSION, HYPERTENSION, ISCHEMIC HEART DISEASE, HYPERLIPIDEMIA, AND PSA. ##. ## RISK FACTORS AND COMORBIDITIES TABLE ## OUTLINES THE RISK FACTORS AND COMORBIDITIES FOR PLAQUE PSORIASIS.

  • Dermatological Condition
  • Drug Development
  • United States
  • World
  • Forecast
  • CLINICAL TRIAL INITIATE IN Q3 2018 BY GEOGRAPHY, GLOBAL
  • CRO Activity in 2018 (Q3)

PLoS One; ##(##): e##.

  • Dermatological Condition
  • Drug Development
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

OTHER COMMON AES INCLUDE DIZZINESS, DEPRESSION, SHORTNESS OF BREATH, BRADYCARDIA, HYPOTENSION, DIARRHEA, PRURITUS, AND RASH.

  • Dermatological Condition
  • Drug Development
  • Market Size
  • Bristol-Myers Squibb Company
  • Les Laboratoires Servier SAS

Depression and mood indicators in newly diagnosed glaucoma patients.

  • Dermatological Condition
  • Drug Development
  • Adverum Biotechnologies, Inc.
  • Alcon, Inc.
  • Allergan plc

IN ADDITION, ONE IN FIVE MEN WITH PCA HAS BEEN REPORTED TO EXPERIENCE DEPRESSION, WITH HALF OF THOSE MEN EXPERIENCING " SEVERE" DEPRESSION (HEIM AND OEI, 1993). ## Epidemiology ##. ## DISEASE BACKGROUND PCA IS A MALIGNANCY IN THE PROSTATE GLAND, WHICH IS LOCATED BELOW

  • Dermatological Condition
  • Drug Development
  • Prostate Cancer
  • United States
  • PROVENGE group
  • 12.7.4 MNM VIEW

It is also working on a complementary genomic depression test that does not require FDA approval.

  • Drug Development
  • Healthcare
  • World
  • Market Size
  • Cogstate Limited
  • 12.7.4 MNM VIEW

It is also working on a complementary genomic depression test that does not require FDA approval.

  • Drug Development
  • Healthcare
  • World
  • Market Size
  • Cogstate Limited
  • BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS, G7 COUNTRIES, CLINICAL TRIALS BY PHASE, 2018*
  • BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS, GLOBAL, CLINICAL TRIALS BY REGION (%), 2018*

BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS,

  • Clinical Trial
  • Dermatological Condition
  • Drug Development
  • Therapy
  • World
  • 3.3 GLOBAL AND HISTORICAL TRENDS
  • 3.1 DISEASE BACKGROUND

MEDICAL ELECTRON MICROSCOPY; ##(##): ##-##.

  • Dermatological Condition
  • Drug Development
  • Japan
  • United States
  • Forecast
  • Psoriasis Therapeutics Market, Australia, Treatment Usage Patterns ('000), 2017-
  • Psoriasis Therapeutics Market, APAC, Types of Psoriasis

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.

  • Dermatological Condition
  • Drug Development
  • Market Size
  • AbbVie Inc.
  • Janssen Biotech, Inc.

According to Office of National Statistics, one in every four UK citizens are affected with depression.

  • Drug Development
  • Pain Relief
  • World
  • Forecast
  • Allergan plc
  • TREATMENT RESISTANT DEPRESSION THERAPEUTICS, G7 COUNTRIES, CLINICAL TRIALS BY TRIAL STATUS, 2018*
  • TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E7 COUNTRIES, CLINICAL TRIALS BY PHASE, 2018*

TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* CLINICAL TRIALS BY PHASE IN E## COUNTRIES TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## CO

  • Clinical Trial
  • Depression
  • Drug Development
  • World
  • Product Initiative

The role of depression in the context of chronic pain conditions such as neuropathic pain is complex, as it is thought that depression can increase the subjective experience of pain and its debilitating effects.

  • Dermatological Condition
  • Drug Development
  • Market Size
  • Allergan plc
  • Amgen Inc.
  • ALLERGAN

WITHIN THE PHARMACEUTICAL INDUSTRY AS A WHOLE, FINANCIAL DEPRESSION, CONSOLIDATION AND ECONOMIC DOWNTURNS HAVE INFLUENCED THE MARKET.

  • Dermatological Condition
  • Drug Development
  • World
  • Market Size
  • Galderma S.A.

PloS one; ##(##): e##, ##-## Montouris G, et al. (2015).

  • Dermatological Condition
  • Drug Development
  • Market Size
  • Eisai Co., Ltd.
  • GW Pharmaceuticals plc
  • CLINICAL TRIALS - THERAPY AREA PERSPECTIVE
  • CLINICAL TRIALS - ENROLLMENT ANALYTICS

Out of these, one drug is in Phase III, four drugs are in Phase II, and one drug is being developed in Phase I.

  • Drug Development
  • Allergan plc
  • Eisai Co., Ltd.
  • Novartis AG
  • Roche Group
  • 2.3.2 Acne Vulgaris
  • 2.7.3 Retinoids

Acne Vulgaris and Depression: A Retrospective Examination.

  • Dermatological Condition
  • Drug Development
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.

Rare AEs include hepatitis, depression and temporary male infertility.

  • Dermatological Condition
  • Drug Development
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.